When to Order Imaging for Lung Cancer: Surveillance After Therapy: ACR Appropriateness Decoded

When to Order Imaging for Lung Cancer: Surveillance After Therapy: ACR Appropriateness Decoded

A patient with a history of Stage II non-small-cell lung cancer, treated six months ago with definitive chemoradiation, presents for a routine follow-up. They feel well, but you know that detecting recurrence early is critical. Do you order a chest CT with or without contrast? Or is a simple chest radiograph sufficient for routine surveillance? Now consider a different patient with a history of small-cell lung cancer who reports a new, persistent headache. The imaging choice here is different and more urgent. The American College of Radiology (ACR) Appropriateness Criteria provide an evidence-based framework for these common clinical decisions, helping you select the right imaging study based on histology, symptoms, and the goal of the examination—whether it’s routine surveillance or a workup for suspected progression.

What Does ACR Lung Cancer: Surveillance After Therapy Cover?

This ACR guideline focuses specifically on imaging for adult patients who have completed definitive treatment for Stage I-III non–small-cell lung cancer (NSCLC) or small-cell lung cancer (SCLC). The criteria are divided into two primary clinical contexts: routine, asymptomatic surveillance and the evaluation of a patient with new or worsening symptoms concerning for cancer recurrence or progression.

These recommendations are designed to guide imaging choices after the initial treatment course is finished. They do not apply to the initial staging of lung cancer, the assessment of treatment response while therapy is ongoing, or the surveillance of patients with metastatic (Stage IV) disease at initial diagnosis. The criteria help differentiate imaging strategies based on the underlying cancer histology (NSCLC vs. SCLC), which have different typical patterns of recurrence and risk profiles for distant metastases, particularly to the brain.

What Imaging Should I Order for Lung Cancer: Surveillance After Therapy? Recommendations by Clinical Scenario

The appropriate imaging for post-treatment lung cancer patients varies significantly based on the cancer type (NSCLC vs. SCLC) and whether the imaging is for routine surveillance or to investigate a specific clinical concern.

For routine surveillance in an adult following treatment of stage I-III non–small-cell lung cancer (NSCLC), a CT chest with IV contrast is rated Usually appropriate. The contrast helps delineate post-treatment changes from true recurrence, especially in the mediastinum, pleura, or chest wall. A CT chest without IV contrast is considered May be appropriate (Disagreement), as it can detect new or growing lung nodules but is less sensitive for non-parenchymal recurrence. Other modalities like chest radiography, MRI, or PET/CT are Usually not appropriate for this routine screening context.

The approach changes for routine surveillance after treatment of stage I-III small-cell lung cancer (SCLC). Due to the high propensity for SCLC to metastasize to the brain, both MRI head without and with IV contrast and CT chest with IV contrast are rated Usually appropriate. This dual focus on both local thoracic disease and central nervous system screening is a key distinction from NSCLC surveillance protocols.

When there is a suspected recurrence or progression in a patient treated for stage I-III NSCLC, the imaging strategy broadens. FDG-PET/CT from skull base to mid-thigh is Usually appropriate to evaluate for both local and distant metastatic disease. For focused evaluation, CT chest with or without IV contrast and MRI head without and with IV contrast (especially for neurologic symptoms) are also Usually appropriate. These studies provide high-resolution anatomic detail to complement the metabolic information from a PET/CT scan.

Similarly, for a suspected recurrence or progression after treatment for stage I-III SCLC, a comprehensive evaluation is warranted. FDG-PET/CT skull base to mid-thigh, CT chest abdomen pelvis with IV contrast, and MRI head without and with IV contrast are all rated Usually appropriate. This reflects the aggressive nature of recurrent SCLC and the need to assess for widespread disease to guide subsequent management.

ACR Imaging Recommendations Table

Adult vs. Pediatric Lung Cancer: Surveillance After Therapy Imaging: Radiation Dose Tradeoffs

The ACR criteria for this topic are specified for adults, as primary lung cancer is exceptionally rare in the pediatric population. However, the provided relative radiation level (RRL) data includes pediatric estimates, which serve as a crucial reminder of the principles of radiation safety. The ALARA (As Low As Reasonably Achievable) principle is paramount in pediatric imaging, as children have a longer life expectancy during which the potential stochastic effects of radiation can manifest, and their developing tissues are more radiosensitive.

For any given CT scan, the pediatric RRL is often in a higher tier or has a different effective dose range compared to adults. This reflects the greater risk per unit of radiation. In clinical situations requiring ionizing radiation for a child or young adult, protocols must be optimized to minimize dose. This includes adjusting technical parameters (kVp, mAs) based on patient size and, whenever feasible, substituting non-ionizing modalities like MRI or ultrasound. For lung cancer surveillance, MRI of the chest is generally considered Usually not appropriate due to technical limitations but may be considered in very specific circumstances in younger patients to avoid cumulative radiation exposure.

Imaging Protocol Details for Lung Cancer: Surveillance After Therapy

Once you’ve decided on the right study, the specific imaging protocol is essential for diagnostic accuracy. High-quality imaging requires correct patient preparation, contrast administration timing, and acquisition parameters. Our protocol guides provide detailed, scannable instructions for the studies recommended in these ACR criteria.

• CT Chest/Abdomen/Pelvis with IV Contrast
• CT Brain Without Contrast

Tools to Help You Order the Right Study

Navigating imaging guidelines and protocols can be complex. GigHz offers several tools designed to support clinicians in making evidence-based decisions and communicating effectively with patients.

The ACR Appropriateness Criteria Lookup provides a searchable interface for the full library of ACR guidelines, covering thousands of clinical scenarios beyond lung cancer surveillance. It helps you find the official recommendations for virtually any clinical presentation quickly.

Our Imaging Protocol Library contains detailed, step-by-step guides for hundreds of imaging studies. These protocols are designed for residents, technologists, and ordering providers to ensure the correct exam is performed with optimal technique.

The Radiation Dose Calculator is a valuable tool for discussing radiation exposure with patients. It helps estimate cumulative effective dose from various imaging studies and contextualizes the risk, supporting shared decision-making and informed consent.

What is the recommended frequency for surveillance CT scans after NSCLC treatment?

Most national guidelines, such as those from the NCCN and ASCO, recommend surveillance with low-dose chest CT every 6 to 12 months for the first 2-3 years after curative-intent therapy for early-stage NSCLC, and then annually thereafter. The exact interval can vary based on the initial stage and risk of recurrence.

Why is routine brain imaging recommended for SCLC surveillance but not for NSCLC?

Small-cell lung cancer (SCLC) has a much higher incidence of brain metastases compared to non-small-cell lung cancer (NSCLC). A significant number of patients with SCLC will develop brain metastases, often as the first site of recurrence. Therefore, routine surveillance with brain MRI is considered appropriate to detect these metastases early, even in asymptomatic patients.

When should I choose PET/CT over a diagnostic CT for suspected recurrence?

FDG-PET/CT is rated Usually appropriate for suspected recurrence because it is a whole-body imaging modality that assesses metabolic activity. It is excellent for detecting unsuspected distant metastases and can help differentiate post-treatment scarring or inflammation from active cancer. A diagnostic CT provides superior anatomic detail of a specific area (like the chest) but does not assess for systemic disease with the same sensitivity as PET/CT.

Is a chest radiograph ever sufficient for lung cancer surveillance?

For routine surveillance after treatment, a chest radiograph is rated Usually not appropriate by the ACR. While it involves very low radiation, its sensitivity for detecting early recurrence, especially small nodules or mediastinal disease, is significantly lower than that of a CT scan. CT is the standard of care for surveillance.

What if my patient has a contraindication to IV contrast, like a severe allergy or renal failure?

If a patient cannot receive iodinated IV contrast, a non-contrast CT of the chest is a reasonable alternative and is rated May be appropriate (Disagreement) for NSCLC surveillance. While less optimal for evaluating mediastinal, hilar, or pleural disease, it is still effective for detecting new or growing lung parenchymal nodules. The clinical team must weigh the diagnostic limitations against the risks of contrast administration.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 12, 2026